Market Research Future (MRFR)’s report on Global Transplant Diagnostics Market showcases that the market will grow at a CAGR of 7.2% during the forecast period (2017-2023) due to the increased demand for organ transplant surgeries. The Market for Transplant Diagnostics is segmented on the basis of products into reagent, instrument, software and services.
Transplant Diagnostics are tests performed to verify the compatibility between the recipient and donor before and after transplantation. With the increase in chronic diseases, the transplant diagnostic market is expected to grow at a faster rate soon.
There have been notable technological advancements in transplant diagnostics to provide better and advanced options for organ transplant. While the emerging regions such as Asia Pacific and Latin America and Middle East and Africa (LAMEA) holds possible opportunities, the market for transplant diagnostics in the developed countries is in a mature phase.
Get Free Sample @ https://www.marketresearchfuture.com/sample_request/1324
Global Transplant Diagnostics Market – Key Players
Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Becton Dickinson and Company (US), Abbott Laboratories Inc (US), CareDx (US), Qiagen N.V. (Netherlands), Immucor, Inc. (US), GenDx (Netherlands), Omixon Ltd. (UK), bioMérieux S.A. (France), Illumina, Inc. (US), Immucor Transplant Diagnostics, Inc (US), Affymetrix, Inc (US), Linkage Biosciences (US)
Global Transplant Diagnostics Market – Segmentation
MRFR’s report states that the Global Market is segmented based on product and service, screening type, organ type, application, and end-users.
By product and service, the market has been segmented on the basis of instruments, reagents & consumables, and software and services. The reagents & consumables segment presently holds the largest market share and is estimated to dominate the market throughout the assessment period.
By screening type, the market has been segmented on the basis of pre-transplant screening and post-transplant screening. The pre-transplant screening segment valued more than USD 819.04 million in 2017.
By organ type, the market has been segmented on the basis of kidney, liver, heart, lung, pancreas, and others. The kidney segment valued more than USD 896.02 million in 2017. Factors attributing to the growth of this segment include increasing cases of organ rejection combined with the side effects of medication.
By application type, the market has been segmented based on research applications, diagnostic applications, and others. Research Applications accounted for the largest share in the transplant diagnostics market in 2017 and is exhibited to retain its position in the market. The diagnostics procedure before and after transplant for research application is rising gradually. Moreover, the cost of diagnostic testing and procedure are known for their affordable prices.
By end-user, the market has been segmented on the basis of commercial service providers, hospitals and transplant centers, research laboratories & academic institutes and others.
Global Transplant Diagnostics Market – Regional Analysis
Geographically, the Global Transplant Diagnostics Market is segmented into four major regions such as Americas, Europe, Asia Pacific and the Middle East and Africa. Among these regions, the Americas are dominating the global transplant diagnostics market owing to the increasing prevalence of chronic diseases leading to organ failure and rapid technological development aiding in the automation of the diagnostic procedures in the healthcare sector of this region.
The Europe region accounts for the second largest share in the global transplant diagnostics market. The transplant diagnostics market in this region is driven by the easy adoption of advanced healthcare technologies, active involvement of the government for spreading awareness, and availability of donated organs due to the initiatives that were taken by the European Commission for organ harvesting.
The Asia Pacific region is anticipated to project significant growth in the global transplant diagnostics market due to the rapid increase in geriatric population and increasing incidences of organ failure in this region. The high investment in stem cell technology for organ development and in-vitro tissue are some of the crucial factors that are driving the transplant diagnostics market in this region.
In December 2018, Novacyt launched two new diagnostic test kits for post-transplant monitoring. These include the genesig Real-Time PCR BK virus (BKV) Kit (CE) and genesig Real-Time PCR Epstein-Barr Virus (EBV) Kit (CE).
December 2018, CareDx Inc. released new data confirming the utility of its AlloSure test to diagnose allograft health in repeat kidney transplant patients.
In May 2018, CareDx, a U.S.-based molecular diagnostics company, has announced the signing of licensing and commercialization agreement with Illumina, a provider of next-generation sequencing solutions. CareDx is now the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product lines which will be used for bone marrow transplantation diagnostic testing and solid organ transplantation diagnostic testing.
TAI Diagnostics which is US based company and develops non-invasive test to monitor patients’ health after they’ve got heart transplants, has scheduled to initiate selling their test early next year. They have generated about $13 million from their investors so far. The company is presently raising more money to supplement its $8.3 million Series A funding round. The extension could bring TAI’s total outside financing to $21 million, the startup’s test measures levels of cell-free DNA, genetic material released by the transplant recipient’s new heart that can enter the bloodstream, to assess whether they are in danger of rejecting the organ.
Thermo Fisher Scientific Acquires Linkage Bio: on July 2017 Thermo Fisher Scientific confirmed the company’s acquisition of Linkage Biosciences for an undisclosed amount, as a result of this acquisition Linkage Biosciences is now a part of Thermo Fisher’s transplant diagnostics business. The company based in South San Francisco, California. Benefits involved from the acquisition include a broader and deeper range of products, a continued commitment to innovation, and expanded support globally.
Browse Complete 100 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/transplant-diagnostics-market-1324
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312